Summary
Vertex Pharmaceuticals Incorporated (VRTX) has entered into a new $500 million senior unsecured revolving credit facility, the "2022 Credit Agreement", effective July 1, 2022. This facility matures on July 1, 2027, and allows for potential increases of an additional $500 million, subject to certain conditions. The proceeds are designated for general corporate purposes, providing Vertex with financial flexibility for its ongoing operations and strategic initiatives. This new credit agreement replaces the company's prior 2019 credit facility, which was terminated and fully repaid upon the establishment of the new agreement. The 2022 Credit Agreement includes provisions for borrowing in U.S. Dollars and certain non-U.S. Dollar alternative currencies, with interest rates tied to either a base rate or a SOFR-based rate, plus an applicable margin that fluctuates based on the Company's Consolidated Leverage Ratio or credit rating. The agreement also includes customary covenants and events of default, with a financial covenant requiring the maintenance of a Consolidated Leverage Ratio of 3.50 to 1.00, extendable to 4.00 to 1.00 following a material acquisition.
Key Highlights
- 1VRTX entered into a new $500 million senior unsecured revolving credit facility (2022 Credit Agreement) on July 1, 2022.
- 2The new facility has a maturity date of July 1, 2027.
- 3There is an option to increase the borrowing capacity by an additional $500 million, subject to certain conditions.
- 4Proceeds from the credit facility are intended for general corporate purposes.
- 5The 2022 Credit Agreement replaces and terminates the previous 2019 Credit Agreement, with all outstanding obligations under the old agreement repaid.
- 6Interest rates are variable, based on a base rate or SOFR-based rate plus an applicable margin, which is linked to the Company's leverage ratio or credit rating.
- 7The agreement includes a financial covenant to maintain a Consolidated Leverage Ratio of 3.50 to 1.00 (or 4.00 to 1.00 post-acquisition).